Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Imunon, Inc.

Get SEC filing alerts via email and in your feed for Imunon, Inc.

IMNN

Imunon, Inc.

About Imunon, Inc.

Imunon is a biotechnology company developing DNA-based immunotherapies and vaccines. Its core platforms include TheraPlas for cancer treatment and PlaCCine for infectious disease vaccines, targeting solid tumors and pandemics like COVID-19. The company focuses on innovative, non-viral delivery systems to generate durable immune responses, with a pipeline emphasizing ovarian cancer immunotherapy and next-generation vaccines for emerging pathogens.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Imunon, Inc.

1
1
Imunon, Inc. Imunon Reports $4.3 Million Net Loss in Q1 2026, Seeks Additional Capital

Via official filing (AI summary) | 27 days ago | 0 comments

2
1
Imunon, Inc. Imunon Reports $14.5 Million Net Loss for Fiscal Year 2025, Advances Clinical Programs

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Imunon, Inc. Imunon Reports $3.4 Million Net Loss in Q3 2025, Seeks Funding for Clinical Trials

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Imunon, Inc. Imunon Reports $2.7 Million Net Loss in Q2 2025, Down from $4.8 Million Last Year

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Imunon, Inc. Imunon Reports $4.1 Million Net Loss in Q1 2025, Decreased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Imunon, Inc. Imunon Reports $18.6 Million Net Loss for Fiscal Year 2024, Faces Funding Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Imunon, Inc. Imunon Reports 27% Increase in Operating Expenses, Net Loss of $4.85 Million in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments